Vivos in The News Explore The Stories Investor RelationsLeadershipFinancial Results & SEC FilingsStock PricingGovernanceNews + Events Menu Investor RelationsLeadershipFinancial Results & SEC FilingsStock PricingGovernanceNews + Events Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company’s Proprietary Oral Medical Devices to Treat Severe OSA Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway” Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea Vivos Reports 2023 Q3 Financial Results and Operational Update Vivos Therapeutics Signs Nationwide Distribution Agreement with Lincare Vivos Therapeutics to Begin Clinical Trial at Stanford Medicine Vivos Announces Collaboration in the Middle East North Africa to Support International Expansion Load More
Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds
Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities
Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company’s Proprietary Oral Medical Devices to Treat Severe OSA
Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea